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Traditionally developed for diagnosis of bleeding disorders, platelet function assays have 
become increasingly used in basic research on platelet physiology, in phenotype-genotype 
associations in bleeding disorders, in drug development as surrogate endpoints of efficacy for 
new antiplatelet therapy, and to an extent, in monitoring of antiplatelet therapy in clinical 
practice to predict thrombotic and bleeding risk. A multiplicity of platelet function assays is 
available to measure the level of platelet activity in various settings. These include assays that 
are restricted to a specialized laboratory as well as point-of-care instruments meant to 
investigate platelet function at patient bedside. Unlike tests that determine a defined quantity 
or measurement of a clinical biomarker (e.g. cholesterol or blood pressure), platelet function 
testing assesses the dynamics of living cells, which immediately presents a series of unique 
problems to any laboratory or clinic. This article presents currently used platelet function 
assays and discusses important variables to take into account when performing these assays, 
including pre-analytical issues and difficulties in interpreting platelet function test results. 
 







New roles for platelets are constantly being discovered, with platelets contributing to 
modulating inflammation, host defense and immunity, wound healing, fetal vascular 
remodeling, tumor growth and metastasis, in addition to their well-established role in 
maintaining hemostasis.1,2 For this multitalented and multifaceted purpose, platelets are a 
treasure trove of membrane receptors and anchoring proteins, diverse granular contents and 
various de novo-generated mediators, which intervene in a coordinated fashion to ensure 
appropriate platelet activation, degranulation and aggregation.3 With numerous redundant 
platelet activation pathways working in concert, platelets are a complex cell to study and 
require specialized methods to capture this diversity of platelet responses. A large array of 
platelet function assays have been developed in response to this challenge, mostly for the 
purpose of diagnosing and managing patients presenting with bleeding problems.4 However, 
as platelets are key contributors to atherothrombosis,5,6 platelet function tests are increasingly 
being used to monitor the efficacy of antiplatelet drugs to inhibit pathological thrombus 
formation, and to try to identify patients at risk of future ischemic or bleeding events.7 
Widespread use of antiplatelet therapy can not be dissociated from its attendant bleeding risk, 
which can be life-threatening in during trauma and surgical procedures. Platelet function 
assays are therefore also being increasingly used as periprocedural tools to aid in the 
prediction and management of periprocedural bleeding.8 The need for on-the-spot results 
along with the development of new, simpler tests and point-of-care instruments, has resulted 
in the increasing tendency of platelet function testing to be performed away from specialized 
clinical or research hemostasis laboratories, where the more traditional and complex tests are 




Specific applications of platelet function assays for the diagnosis of bleeding 
disorders,9 granule secretion disorders,10 and monitoring of antiplatelet therapy11 are 
discussed in more detail elsewhere in this issue of the journal. This article presents currently 
used platelet function assays and discusses important variables to take into account when 
performing these assays, including pre-analytical considerations and difficulties in 
interpreting platelet function assay results. 
DUKE-IVY BLEEDING TIME, A PRELUDE TO PLATELET 
FUNCTION TESTING 
Initially described as a coagulation test by M.G. Milian in 1901, the test subsequently 
known as the Duke-Ivy Bleeding Time was first successfully demonstrated to correlate with 
platelet dysfunction by W.W. Duke in 1910.12,13 The bleeding time was further refined by A. 
C. Ivy in 1941, who standardized the assay by applying a blood pressure cuff to the upper 
arm inflated to 40 mm Hg and making a 5 mm long by 1 mm deep longitudinal incision on 
the ventral surface of the forearm where skin thickness is uniform.14 The technique consists 
of recording the time required for a blood clot to form at the site of the incision and stop 
blood flow. Following the 1961 report by C.H. Mielke of a template to further standardize 
bleeding time,15 the commercial spring-loaded devices containing sterile blades (e.g. 
Simplate II® by the Organon Teknika Corporation and later Surgicutt® by the International 
Technidyne Corporation) have made the bleeding time the most useful screening test of 
platelet function until the early 1990’s.16 
The bleeding time is simple and does not require expensive equipment or a 




adhesive proteins such as von Willebrand factor (VWF), and integrates the interplay of the 
blood components with the vessel wall. However, despite the use of standardized devices, the 
bleeding time is poorly reproducible, invasive, insensitive to many mild platelet defects and 
time-consuming. In addition, an accurate bleeding history is a more valuable screening test, 
as it captures mild bleeding tendency more robustly than the bleeding time.17-19 As a result, 
widespread use of the bleeding time has rapidly declined over the last 20 years, to be replaced 
by other less invasive platelet function assays carried out ex vivo on freshly collected blood 
samples.20  
PRE-ANALYTICAL VARIABLES 
Recent surveys have highlighted important differences between laboratories in platelet 
function testing practices.21-24 These differences may explain some of the variability reported 
between laboratories, but also emphasize the importance of controlling for pre-analytical 
variables when performing platelet function assays. Some of the key considerations are 
detailed below, as failure to apply these precautions may lead to spurious results.20 With the 
exception of PFA-100/200® where quality controls have been proposed,25,26 there are no 
widely available internal or external quality control materials available for platelet function 
testing.27 Most assays are performed on fresh blood and so many laboratories either establish 
normal ranges using control blood obtained from healthy volunteers and/or assay samples 
known to be normal in parallel to ensure that each test/reagent is viable.28 
Blood sampling conditions 
Several conditions have been shown to influence platelet function, including circadian 




and smoking.34 Although ideally, samples for platelet function studies should only be 
collected from fasting and resting subjects who have refrained from smoking, caffeine 
ingestion and rigorous exercise on the day of testing, as well as medication or substances 
known to affect platelet function (which include non-steroidal anti-inflammatory drugs, 
antiplatelet agents, phosphodiesterase inhibitors, certain psychotropics and herbal remedies) 
for 10-14 days, pragmatically many of these conditions are hard to control.20,35,36 An 
unexpected finding in platelet function results should, however, prompt investigations into 
these potential confounders, and repeat testing on a fresh blood sample under more suitable 
conditions may be warranted. 
Venipuncture  
Blood should be collected from the antecubital vena fossa by an experienced 
phlebotomist applying a standardized, atraumatic protocol of a clean venipuncture using 
minimum tourniquet pressure.20 To avoid sheer-induced platelet activation, 19-21 gauge 
needles or butterfly cannulae should be used, in conjunction with either an evacuated tube 
system or plastic syringe. Traditionally, the first 5-ml / tube collected should be discarded to 
avoid tissue factor-induced aggregation from the venipuncture, but this practice is rarely 
applied in clinical centers and evidence of nefarious effects is lacking.37 Underfilling or 
overfilling of collection tubes is an important problem, and efforts should be made to filling 
the tube to 90% capacity or to the manufacturer-specified mark to avoid incorrect sample 
dilution / anticoagulation.37 Samples should be handled gently and inverted three to six times 





For clinical platelet function testing, the most commonly employed anticoagulant is 
trisodium citrate (105-109 mM final concentration).20 Other commonly used anticoagulants 
include hirudin, D -phenylalanyl- L -prolyl- L -arginine chloromethyl ketone (PPACK) a 
potent thrombin inhibitor, heparin, the dual thrombin/factor Xa inhibitor benzylsulfonyl-D-
Arg-Pro-4-amidinobenzylamide (BAPA), and acid-citrate-dextrose (ACD). Although there is 
a healthy debate about the most suitable anticoagulant for platelet function testing,38 most 
assays can be performed in samples anticoagulated with any of these agents. However, if 
EDTA-containing tubes are required (e.g. for complete blood counts), these should be 
collected last to avoid potential carryover effects.37 
Specimen processing 
All blood samples should be maintained at ambient temperature (20-25 °C) and 
should not be placed in a refrigerator/ice pack or in a warm water bath prior to platelet 
function testing.20 Transport of samples should avoid vibration, shaking, vortexing or 
agitation; as such, pneumatic tube systems are considered inappropriate for transporting 
platelet function testing specimens.39 The time delay between collection, transport and 
analysis should ideally be between 30 min and 2h, but no more than 4h.20 
If preparation of platelet-rich plasma (PRP) is required, centrifugation of whole blood 
samples should be at 200g for 10 min, at ambient temperature without using a brake.36 This 
maximizes the quality of PRP by reducing contamination with other blood cells and 
optimizing platelet reactivity.40 Platelet-poor plasma (PPP) should be prepared by 
centrifuging whole blood, or the tubes of blood from which PRP was removed, at ambient 




to a standardized value with autologous PPP, as this practice alters platelet reactivity.41,42 
PLATELET FUNCTION ASSAYS 
Increasingly, platelet function instruments are easy to use and have made their way 
outside of specialized laboratories. However, the more involved and complex assays remain 
restricted to specialist centers, as they require not only expensive machinery, but perhaps 
more importantly, expertise and a relatively high volume of testing to maintain test quality 
and facilitate interpretation of results. Some tests are meant as global screening tests of 
platelet hemostatic function, but most tests are specific assays that assess platelet responses, 
either in whole blood or in PRP. Table 1 provides a summary of currently available platelet 
function tests, their major advantages and disadvantages as well as frequency of use. The 
more commonly used assays are described in more detail below. 
Light transmission aggregometry 
Considered the historical gold standard, light transmission aggregometry (LTA) 
measures platelet aggregation as a function of light transmission through PRP, a turbid 
suspension of cells  relatively opaque to light transmission.43 As platelets start to aggregate in 
response to a platelet agonist, turbidity of the suspension is reduced and translates into in 
increased light transmission (PPP being used to define 100% light transmission). The 
dynamics of platelet aggregation (expressed as %) is therefore measured in real time as 
platelets aggregate. An adaptation of this technology allows for luminescence to be read 
concomitantly to light transmission, thus measuring secretion of nucleotides from dense 
granules during aggregation by using a luciferin-luciferase substrate added to PRP. 44 




induced by numerous agonists in varying concentrations.20,45 Kinetic information of platelet-
platelet interactions that is gleaned from this assay corresponds with specific phases of 
platelet activation, from shape change to degranulation and unstable vs. firm platelet 
aggregation as confirmed by electronic microscopy (Figure 1).46 As a result, LTA offers the 
possibility of studying platelet activation pathways in detail, and has been the preferred 
platelet function assay in most specialized laboratories over the last 50 years.  
On the other hand, LTA is relatively non-physiological, as platelets are isolated from 
other whole blood components, stirred under low shear conditions and only form aggregates 
after addition of agonists.  These conditions do not entirely mimic platelet adhesion, 
activation and aggregation as they would occur in response to damage to the vessel wall.28 
Conventional LTA using a full panel of agonists requires large blood volumes and significant 
expertise to perform the tests and to interpret the tracings,47 which has triggered attempts at 
automation of LTA,48 as well as development of new, easier-to-use platelet function assays. 
High throughput adaption of LTA using 96-well plates 
In an attempt to palliate some of the difficulties in performing LTA, including the 
requirement for a large blood volume, for dedicated machinery and for experienced 
personnel, several laboratories have developed a modified technique based on light 
transmission principles but applied to standard 96-well plates.49-51 Platelet agonists either in 
solution or pre-coated onto wells are used to trigger platelet aggregation upon addition of 
PRP.  When the plate is stirred, the formation of platelet aggregates changes the absorbance 
of light passing through the 96-well plate, which can be measured either kinetically or as an 
endpoint (e.g. after 5 minutes) in a conventional plate reader. Absorbance is then converted 




PRP and PPP samples.51,52 Example results from a healthy volunteer obtained using the 
Optimul assay are shown in Figure 2.52 
This technique can provide a rapid assessment of most platelet activation pathways 
within minutes, including detailed dose-response curves which are rarely obtainable from 
LTA due to blood volume restrictions, the number of channels available and time.53 The 
assay is a promising tool for screening of bleeding disorders and monitoring of antiplatelet 
therapy, as well as understanding basic pathophysiology of platelets.53-55  
Whole blood aggregometry 
Whole blood aggregometry (WBA) is based on a change in electrical impedance 
resulting from platelet aggregation, in response to classical agonists, onto two electrodes 
immersed directly in saline-diluted whole blood.56 The Multiplate® instrument is the most 
widely used apparatus in clinical laboratories, as it is semi-automated and uses disposable 
cuvettes/electrodes with preselected agonists for different applications, including diagnosis of 
bleeding and monitoring of antiplatelet therapy.57-59 
As its name states, WBA is performed in whole blood, which is among its main 
advantages as opposed to LTA. However, a number of factors are known to influence WBA, 
which include hematocrit and platelet count, the anticoagulant used, and the delay between 
blood sample collection and platelet function testing.38,60-62 The use of smaller sample 
volumes, no requirement of prior sample manipulation by centrifugation, which reduces the 
risk of platelet activation or potential loss of platelet subpopulations, as well as gains in time 
make it an interesting clinical assay, especially in the monitoring of antiplatelet therapy and 
as a perioperative assay.59,63 The paucity of published data on platelet dysfunctions with these 





Specifically developed to monitor antiplatelet therapy, the VerifyNow® system is 
fully automated point-of-care test where fibrinogen-coated polystyrene beads agglutinate in 
whole blood in response to either arachidonic acid (Aspirin cartridge), ADP and 
prostaglandin E1 (PGE1; P2Y12 cartridge) or thrombin receptor activating peptide (TRAP; 
GPIIbIIIa cartridge). Although it is robust and highly standardized, a number of factors 
influence the performance of the assay, which include fibrinogen levels, hematocrit and 
platelet count, blood triglyceride levels and time from blood sampling to testing.65,66 Lately, 
there has been some question as to the clinical usefulness of the assay, because large clinical 
trials using VerifyNow® P2Y12 to guide antiplatelet therapy have failed to show benefit.7  
Nonetheless, VerifyNow® P2Y12 remains recommended in consensus documents as a 
predictor of future cardiovascular and bleeding events.59 
Platelet Function Analyzer (PFA-100/200®) 
The PFA-100® instrument has been recently updated to PFA-200®.26 It is a cartridge-
based assay, in which a small volume of blood is aspirated through an aperture in a 
membrane coated with platelet agonists until the aperture is completely occluded by a platelet 
plug, which is reported by the system as “closure time”.  Three cartridges are currently 
available; the CADP cartridge contains collagen and ADP, the CEPI cartridge contains 
collagen and epinephrine and the INNOVANCE P2Y cartridge contains ADP and PGE1 
supplemented with calcium, with a smaller aperture (100 µm vs 150 µM).55,56 The 
INNOVANCE P2Y cartridge was developed in view of relative insensitivity of previous 
cartridges to P2Y12 receptor inhibitors, and appears promising in evaluating congenital 




This global test of platelet function is easy to use, rapid, requires a small volume of 
blood (0.8 ml) and does not require substantial specialist training. Platelet count and 
hematocrit influence closure time, and results need to be carefully interpreted in patients with 
a platelet count below 50 x 109/L or hematocrit below 25%.71 Blood group O was associated 
with longer closure times than non-O groups, which should be taken into account when 
deriving normal ranges.72 The closure time is also influenced by the concentration of sodium 
citrate used as anticoagulant, with 3.8% giving greater stability of results.73 The test is highly 
dependent on VWF levels because of the high-shear conditions within the cartridge capillary 
and aperture, which makes it suitable for screening of von Willebrand disease, but makes it 
unsuitable for platelet function testing in this cohort.74,75 In view of the limited sensitivity of 
the PFA-100® in the detection of mild platelet function defects including secretion and 
release defects, a normal PFA-100® result is useful in ruling out a significant platelet defect 
in a patient whose clinical history for bleeding is unlikely to point to an inherited platelet 
disorder, but should not be used as evidence of absence of a platelet defect in patients at high 
suspicion of inherited platelet dysfunction, where specific assays of platelet function are 
preferable.20,76  
Thromboelastography® (TEG®) 
Thromboelastography® (TEG) and Rotational TEG (ROTEG® or ROTEM®) are 
similar technologies that assess the hemostatic function as a whole, from thrombus formation 
to lysis. 77,78 The assays use whole blood incubated in a heated cup in which a pin, connected 
to a computer, is suspended. In the TEG, the cup oscillates whereas in the ROTEG or 
ROTEM, the pin oscillates. In normal anticoagulated blood, the pin is unaffected, but as a 




depicting clot strength. Whole blood or re-calcified plasma can be used, with or without 
activators of the tissue factor or contact factor pathways.77 Arachidonic acid and ADP can be 
used as agonists to pre-activate platelets within the TEG system (PlateletMappingTM 
technology).  As such, the assay is theoretically suitable to study platelet function and 
monitor antiplatelet drugs, but the test lacks sensitivity to detect moderate changes in platelet 
function.77,79,80  
TEG®/ROTEM® tests are relatively rapid to perform (<30 minutes) and have 
traditionally been used as point-of-care tests during surgery. Their main advantage is to 
provide a complete profile of clot formation, including the kinetics of clotting, clot strength 
and fibrinolysis. Both tests thus provide a global portrait of clot formation within whole 
blood and allows for interactions between whole blood elements including platelets and the 
coagulation system. A group of investigators from different countries have formed the TEG-
ROTEM Working Group, with the intention to standardize assay performance, and increase 
reproducibility and consistency using TEG®/ROTEM.81 Their initial observations suggest 
that there is significant inter-laboratory variation. Also, both tests exhibit relative insensitivity 
to various aspects of platelet function and they are therefore not routinely recommended for 
platelet function testing.  
Flow cytometric analysis of platelet function 
Flow cytometry is a laser-based technology that provides a wealth of information on 
individual cells based on the scatter of light that they produce as they cross the light source.  
It is a powerful and popular tool to study many aspects of platelet biology and function, and 
its recent developments are described in a separate paper in this issue.82 Investigations are 




including antibodies and dyes that bind specifically to individual platelet proteins, granules 
and lipid membranes.83 Platelet function is usually studied as a change in expression of 
activation markers (most commonly P-selectin expression on the platelet surface as a marker 
of α-granule secretion and the conformational change in integrin αIIbβ3 into its active state 
with the PAC-1 antibody), in the appearance of heterocellular aggregates (most commonly 
platelet-leukocyte conjugates) and as change in signaling pathways (most commonly 
phosphorylation of vasodilator-stimulated phosphoprotein [VASP] as a marker of P2Y12 
receptor activation-dependent signaling).84,85 Fixation of samples allows for use of a core 
facility for analysis, thus rendering the assay more accessible to non-specialist settings.84 An 
important advantage of flow cytometry is that it can be performed independently of platelet 
count, making it potentially suitable for assessing platelet function in patients with 
thrombocytopenia.86 The interpretation of results remains somewhat subjective, which makes 
the results of this assay difficult to compare from one laboratory to another; however, efforts 
have been made to standardize the use of flow cytometry for platelet function testing.84,87 
CONCLUSION 
The last 50 years have truly been a golden era for platelet function testing. The use 
of LTA and later flow cytometry have driven our understanding of platelet biology, 
physiology and pathology.88 In parallel, the understanding of platelet targets for effective 
thrombotic inhibition has led to a wide arsenal of antiplatelet drugs being developed.89 The 
availability of easy to use point-of-care assays have taken platelet function testing outside of 
specialized hematology laboratories and closer to the patient. Today’s challenges in platelet 
function testing include determining the true clinical usefulness of these assays for predicting 




in individual patients.7,90  
Platelet function testing is at the cusp of a new era, that of precision medicine and 
deep phenotyping. Comprehensive platelet function testing is increasingly being investigated 
in research settings, where platelet biology and physiology drive understanding of complex 
biological systems, including inflammation, immunity and cancer. New approaches to LTA, 
including automation and transfer to 96-well plate-based assays, as well as novel microfluidic 
assays appear particularly promising for deep phenotyping of platelet responses.48,53,91 The 
future of platelet function testing will need to harvest the wealth of data generated by high 
throughput deep phenotyping approaches and translate these platelet function findings into 
actionable determinants of disease, with ideally pharmacological targets to influence 
progression of disease. Platelet function testing is therefore at a particularly interesting stage, 
as the development of new technologies and new instruments may have future utility in a 
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Table 1: Non-exhaustive list of commonly used platelet function assays 
Name of Test Principle Advantages Disadvantages Frequency of Use 
Global assays of hemostasis 
Bleeding time In vivo cessation of blood flow In vivo test, physiological POC Insensitive, invasive, scarring, high 
CV 
Was widely used, now 
less popular 
Thromboelastography 
(TEG® or ROTEM®) 
Monitoring of rate and quality of clot 
formation 
Global whole blood test, POC Measures clot properties only, 
largely platelet-independent unless 
platelet activators are used 
Widely used in surgery 
and anesthesiology 
Electron microscopy Ultrastructural analysis of platelets Diagnostic 
Whole mount technique useful 
for dense granular imaging 
Expensive, specialized equipment Only available in special 
units 
Platelet activation-based assays 
Flow cytometry Measurement of platelet glycoproteins 
and activation markers by fluorescence 
Whole blood test, small blood 
volumes, wide variety of tests 
Specialized operator, expensive, 
samples prone to artifact unless 
carefully prepared 







Flow cytometric or ELISA 
measurement of phosphorylation of 
VASP 
 
Measurement of P2Y12 
receptor signalling 
 
Insensitive to intermediate 




Platelet aggregation-based assays 
Light transmission 
aggregometry (LTA) 
Low shear platelet-to-platelet 
aggregation in response to classic 
agonists 
Gold standard Time-consuming, sample 
preparation, poorly standardized 
Widely used in 
specialized labs 
96-well-plate based 
assays in PRP 
Based on LTA principles Lower blood/PRP volumes 
than LTA. Many replicates and 
dose-response curves possible 
Little widespread experience Little widespread 
experience 
Plateletworks® Platelet counting pre- and post-
activation 
Rapid, simple, POC, small 
blood volume 
Indirect test measuring count after 
aggregation 
Used in surgery and 
cardiology 
VerifyNow® Fully automated platelet aggregometer 
to measure antiplatelet therapy 
Simple, POC, 3 test cartridges 
(aspirin, P2Y12, and GPIIb-
Inflexible, cartridges can only be 






WBA Monitors changes in impedance in 
response to classic agonists 
Whole blood test, multichannel 
version available 
Dependent on platelet count, older 
instruments require electrodes to be 
cleaned and recycled 
Widely used in 
specialized labs although 
less than LTA 
Shear-based assays 
PFA-100/200® High-shear platelet adhesion and 
aggregation during formation of a 
platelet plug 
Whole blood test, high shear, 
small blood volumes, simple, 
rapid, POC 
Inflexible, VWF-dependent, Hct-




Miniaturized multichannel devices 
 
Whole blood, real-time 
thrombus formation 
Little widespread experience 
 
Research only at present 
Assays measuring platelet release reactions 
Lumi-aggregometry Combined WBA or LTA and 
nucleotide release 
Monitors release reaction with 
secondary aggregation 
Semiquantitative Widely used in 
specialized labs, although 
less than LTA 




nucleotides by luminescence or HPLC calibration, extra equipment labs 
Soluble platelet release 
markers and sheddome 
(e.g. serotonin, PF4, 
βΤG, sCD40L, 
sCD62P, GPV and 
GPVI) 
Usually by ELISA Relatively simple Prone to artifact during blood 
collection and processing 
Fairly widely used in 
research 
Serum thromboxane B2 Immunoassay Dependent upon platelet COX-
1 activity 
Prone to artifact Widespread use 
AspirinWorks® Immunoassay of urinary 11-
dehydrothromboxane B2 
Measures stable thromboxane 
metabolite, dependent upon 
COX-1 activity 




COX-1, cyclooxygenase 1; CV, coefficient of variation; ELISA, enzyme-linked immunoassay; GP, glycoprotein; Hct, hematocrit; HPLC, high-performance liquid 




PRP, platelet-rich plasma; sCD40L, soluble CD40 ligand; sCD62P, soluble CD62P (P-selectin); βΤG, β-thromboglobulin; VASP, vasodilator-stimulated phosphoprotein; WBA, 






Figure 1: Morphological changes of washed platelets during ADP-induced aggregation 
An aggregation response was obtained by stimulating platelets with 5 μM ADP (arrow). The 
platelets were fixed at different time points and their surface features were visualized by 
scanning electron microscopy (SEM). (A) Discoid cells in the resting state. (B) Formation of 
early pseudopods (7 s). (C) Full shape change and first platelet-platelet interactions (20 s). 
(D) Large platelet aggregates (45 s). (E) Isolated platelets after disaggregation (3 min). Bars = 
1 μm. 
 
Reproduced with permission from: Cazenave JP, Ohlmann P, Cassel D, Eckly A, Hechler B, 
Gachet C. Preparation of washed platelet suspensions from human and rodent blood. Methods 
Mol Biol 2004; 272: 13-28. Copyright © 2004, Humana Press Inc. 
 
Figure 2: Example results from the Optimul assay 
Dose-response curves obtained with Optimul in a healthy volunteer, using 2.5 ml of platelet-
rich-plasma. 
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